Table 1 Clinical characteristics of 117 patients with AITL.
From: B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma
Characteristic | Median | Rang | No. | % |
|---|---|---|---|---|
Male sex | 76/117 | 65.0 | ||
Age (year) | 62 | 19–84 | ||
Age >60years | 67/117 | 57.3 | ||
ECOG PS ≥2 | 19/117 | 16.2 | ||
Stages III or IV | 110/113 | 97.3 | ||
Stage IV | 65/113 | 57.5 | ||
Extranodal involvement | 80/113 | 70.8 | ||
Extranodal sites >1 | 52/113 | 46.0 | ||
BM involvement | 16/100 | 16.0 | ||
Liver involvement | 15/113 | 13.3 | ||
Spleen involvement | 51/113 | 45.1 | ||
B symptoms | 78/117 | 66.7 | ||
Rash/Pruritus | 35/117 | 29.9 | ||
Hemoglobin (g/L) | 109 | 39–160 | ||
Anemia* | 86/117 | 73.5 | ||
Platelet (x109/L) | 172 | 11–466 | ||
<150 × 109/L | 43/117 | 36.8 | ||
Lymphocyte (x109/L) | 1.0 | 0.2–6.9 | ||
≤1.1 × 109/L | 65/117 | 55.6 | ||
Eosinophil (x109/L) | 0.16 | 0–2.34 | ||
≥0.5 × 109/L | 22/117 | 18.8 | ||
Monocyte (x109/L) | 0.62 | 0.02–2.4 | ||
≥0.6 × 109/L | 59/117 | 50.4 | ||
LDH (U/L) | 301 | 126–1020 | ||
LDH level ≥245 U/L | 87/116 | 75.0 | ||
β2 microglobulin (mg/L) | 4.38 | 1.22–14.87 | ||
β2 microglobulin level ≥4.0 mg/L | 67/115 | 58.3 | ||
Serum albumin (g/L) | 33.55 | 16.2–46.3 | ||
Serum albumin level ≤35 g/L | 64/114 | 56.1 | ||
Serum globulin (g/L) | 30.9 | 17.3–70 | ||
Serum globulin level ≥35 g/L | 42/114 | 36.8 | ||
IPI score | ||||
Low risk | 7/113 | 6.2 | ||
Low-intermediate risk | 26/113 | 23.0 | ||
High-intermediate risk | 44/113 | 38.9 | ||
High risk | 36/113 | 31.9 | ||
PIT score | ||||
Group 1 | 8/100 8.0 | |||
Group 2 | 36/100 36.0 | |||
Group 3 | 42/100 42.0 | |||
Group 4 | 14/100 14.0 | |||
Pathological finding | ||||
EBER (+) | 49/69 | 71.0 | ||
CXCL13 (+) | 57/77 | 74.0 | ||
BCL-6 (+) | 66/78 | 84.6 | ||
CD10 (+) | 61/92 | 66.3 | ||
PD-1 (+) | 28/29 | 96.6 | ||
